Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Anticancer Drugs. 2013 Oct;24(9):986-8. doi: 10.1097/CAD.0b013e328363b64e.

Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma.

Author information

  • 1Division of Gynecologic Oncology, Cleveland Clinic Health System, Ohio 44195, USA. rosep@ccf.org


A patient with platinum resistant low-grade serous ovarian carcinoma had an objective response to therapy with bevacizumab and evidence of extended activity (>7 years). This case report adds to the growing literature regarding the use of bevacizumab in low-grade serous ovarian carcinoma.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk